#GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the #immunecheckpointreceptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in #lungcancer.
pharmaphorum.com/news/gsk-suf...
1
0
0
0
